Camurus AB (CAMX) Price & Analysis

Camurus AB released its earnings results on Nov 06, 2025. The company reported kr3.27 earnings per share for the quarter, missing the consensus estimate of kr3.298 by -kr0.028.

Is Camurus AB overvalued?

According to Wall Street analysts Camurus AB’s price is currently Overvalued. Get more investment ideas with TipRanks Premium

Does Camurus AB pay dividends?

Camurus AB does not currently pay dividends.

What is Camurus AB’s EPS estimate?

Camurus AB’s EPS estimate is 2.04.

How many shares outstanding does Camurus AB have?

Camurus AB has 59,848,633 shares outstanding.

What happened to Camurus AB’s price movement after its last earnings report?

Camurus AB reported an EPS of kr3.27 in its last earnings report, missing expectations of kr3.298. Following the earnings report the stock price went down -5.862%.

Which hedge fund is a major shareholder of Camurus AB?

Currently, no hedge funds are holding shares in SE:CAMX

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Company Description

Camurus AB

Camurus AB (publ), a pharmaceutical company, develops and commercializes medicines for severe and chronic conditions in Europe, Australia, the United States, Japan, and internationally. The company offers Buvidal, a buprenorphine injection for the treatment of opioid dependence; episil oral liquid, a medical device for the treatment of inflammatory and painful conditions in the oral cavity; and Brixadi to treat opioid use disorder Its products pipeline also includes CAM2038 for the treatment of chronic pain; CAM2029, which is in phase III clinical trials for the treatment of acromegaly and neuroendocrine tumors, as well as in phase II clinical trial to treat polycystic liver diseases; and CAM2043 that is in phase I clinical trial for the treatment of pulmonary arterial hypertension, as well as in Phase II clinical trial to treat Raynaud's phenomenon. In addition, the company is developing CAM2032, which is in phase II clinical trials for the treatment of prostate cancer; CAM4072 that is in phase III clinical trials for the treatment of genetic obesity disorders; CAM4071, which is in phase I clinical trials for the treatment of endocrine disorder; CAM2047 for the treatment of chemotherapy-induced nausea and vomiting that is in phase 1 clinical trial; and CAM2048, which is in phase I clinical trial for postoperative pain. Camurus AB (publ) was founded in 1991 and is headquartered in Lund, Sweden.

Camurus AB (CAMX) Earnings & Revenues

Historic Earnings Reports

CAMX Company Deck

CAMX Earnings Call

Q3 2025

0:00 / 0:00

Earnings Call Sentiment|Neutral

The earnings call presented a mixed outlook with both significant achievements and notable challenges. Camurus showed strong revenue growth, profitability, and positive R&D developments, but faced hurdles with lowered revenue guidance, slowed Buvidal sales, and funding issues in the U.K. market.View all SE:CAMX earnings summaries